Symbols

JANX

Janux Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About JANX

Janux Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing immunotherapies for cancer

Industry

Pharmaceutical

Established Date

06/27/2017

Listing Date

06/11/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

109

Fiscal Year Ends

12-31

Website

www.januxrx.com

Security Type

Common stock

Office address

10955 Vista Sorrento Parkway, Suite 200, San Diego, California, 92130

Business

Introduction

Janux Therapeutics, Inc., was incorporated in Delaware on June 27, 2017. The Company is an innovative biopharmaceutical company developing next-generation therapies based on the Company's proprietary Tumor-Activated T-Cell Enginator (TRACTr) platform technology to better treat cancer patients. The company's initial focus is to develop a new class of T-cell adapters (TCE), and the company's main product candidates are designed for clinically validated drug targets.

Company Financials

EPS

JANX has released its 2025 Q4 earnings. EPS was reported at -0.51, versus the expected -0.62, beating expectations. The chart below visualizes how JANX has performed over recent quarters, highlighting trends in earnings surprises.